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The main aim of the present report is to show the potential utility of bone scintigraphy for the diagnosis of jaw 
osteonecrosis. We report the history of a 62-year-old woman underwent breast cancer surgery in 2010. Moreover, 
patient received postoperative radiotherapy and chemotherapy. Intravenous bisphosphonates were also added to the 
treatment strategy to reduce the risk of bone metastasis. However, a hypermetabolic focus on left hemimandible 
was evidenced with a bone scintigraphy during follow up. After a careful study, the diagnosis of Bisphosphonate 
Related Ostneonecrosis of the Jaw (BRONJ) was carried out. This case highlights that bone scintigraphy may be 
extremely helpful for the early detection of BRONJ in high risk patient.




Bisphosphonate Related Ostneonecrosis of the Jaw 
(BRONJ) associated with the use of intravenous bis-
phosphonates was described by Ruggiero in 2004 (1). 
Bisphosphonates work by modulating the following ce-
llular activities:  decrease of bone resorption due to in-
hibition of osteoclastic activity, induction of osteoclasts 
apoptosis, antiangiogenic action and alteration of the 
physiological bone turnover. Consequently, the bone 
becomes more fragile and its repair capacity is also re-
duced (2,3). In this context, the terminal vascularization 
and the poor soft tissue coverage of the maxilla facilitate 
the appearance of BRONJ. This complication may be 
serious and invalidating and undoubtedly represents a 
tough challenge for all oral and maxillofacial surgeons. 
Early diagnosis is essential to prevent severe sequels and 
to improve patient quality of life. The main objective of 
this paper is to report the utility of bone scintigraphy for 
the early detection of BRONJ.
Case Report
We describe the case of a 62 years old woman underwent 
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breast cancer surgery and axillar dissection in 2010 due 
to a ductal breast carcinoma (pT2N1M0). Patients re-
ceived postoperative chemotherapy (Taxotere-Epirrubi-
cine) and radiotherapy (50Gy) Intravenous bisphospho-
nates (Zometa ® 4mg monthly 4 per month) were also 
used to prevent bone metastasis, following this line. 
A bone scintigraphy was performed two years after sur-
gery as a routine control. Interestingly, hypermetabolic 
focus on right shoulder and left mandible were obser-
ved by this test. The increase in contrast uptake on the 
shoulder area was attributed to a chronic arthralgia. On 
the other hand, the evaluation of the focus involving left 
mandible was more difficult (Figs. 1,2). Intraoral exa-
mination did not show any significant finding, as well 
as the orthopantomography. However, an ulceration 
of the oral mucosa with clinical suppuration and bone 
exposition was observed three months later. A CT-scan 
showed radiological findings of BRONJ such as osteos-
clerosis and bone sequestration (Fig. 3). A biopsy finally 
confirmed the diagnosis of BRONJ. Patients was treated 
with surgical curettage of the area, soft tissue remode-
Fig. 1: Bone scintigraphy that 
shows gadolinium enhance-
ment. Enhancement on the right 
shoulder corresponds to chronic 
arthralgia. Enhancement on the 
left hemimandible is related to 
subclinical BRONJ.
Fig. 2: Pathological enhancement on left hemi-
mandible (detail).
Fig. 3: CT scan with osteosclerosis and bone sequestration areas, 
related to advanced stage BRONJ (red arrow).
lling and medical treatment (oral amoxicillin/clavulanic 
acid 875/125 mg, 3 times a day, 15 days, associated with 
chlorhexidine 0.12% mouthwash 2-3 times a day).
Clinical evolution was favourable and patients and no 
recurrences were observed during follow up.
Discussion
The uptake mechanisms of Bisphosphonates have not 
been completely clarified.
Several radiological test (functional, metabolic or mor-
phologic) may be useful for the diagnosis of BRONJ (4). 
Bone scintigraphy is essential in assessing and classify 
patients affected by malignant tumours. Nowadays, it re-
presents one of the most sensitive tests for bone metas-
tasis detection. Moreover, it is extremely cost-effective. 
Technetium-99mm is the most commonly used medical 
radioisotope (5). 
However, this test is not common in the early diagnosis 
of BRONJ and this represent the first case describing the 
clinical applications of bone scintigraphy for the early 
detection of this pathology. Orthopantomography, CT 
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scan and MRI represent the tests most commonly used 
to diagnose BRONJ (6).
 However, several studies reported that CT scan might 
not show any significant findings at early stage (7,8) and 
it would not be useful for the early diagnosis of this pa-
thology (9). In this sense, Mori et al remark the helpful-
ness of the MRI in the early diagnosis of asymptomatic 
BRONJ (10-13)
Other authors also proposed the use of other techniques, 
as Positron-Emission Tomography (PET) with fluoro-
deoxyglucosa. It could be performed associated with CT 
scan, perceiving early metabolic changes which are un-
detectable with simple clinical imaging (14).
The analysis of our case shows the fast evolution of 
BRONJ (2 years after the beginning of Zometa® treat-
ment) in a patient treated with high power intravenous 
Bisphosphonates. This occur even in absence of preci-
pitant risk factor is as reported by other authors (15). 
Hence, it is widely known the need of a close follow-up 
in the prevention of BRONJ.
In conclusion, this case suggests that functional changes 
in medulla and bone may precede the structural altera-
tions detected with conventional tests. This highlights 
the potential need of developing a protocol for the early 
detection of BRONJ in high risk patients. In this scena-
rio, bone scintigraphy may be extremely useful. 
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